Abstract 93P
Background
New predictive biomarkers for cetuximab-resistance for patients with RAS wild-type colorectal liver metastases (CRLM).
Methods
216 patients with initially unresectable liver-limited RAS wild-type CRLM were identified from previous clinical studies. Among these patients, 103 patients received chemotherapy (mFOLFOX6 or FOLFIRI) plus cetuximab, and 113 received chemotherapy alone as first-line treatment. Next-generation sequencing of primary tumors was done for single nucleotide polymorphism according to custom panel. The patients receiving cetuximab-based chemotherapy were divided into two groups: one group was cetuximab-resistant group and the other group was cetuximab-sensitive group. Potential predictive biomarkers were determined by “random forest" machine learning.
Results
Ten potential predictive genes, namely RET, PTPN11, FLT3, AKT1, ACTN4, ERBB4, FGFR3, MDC1, CUL9, and ZNF462, were identified. In the cohort of cetuximab-based chemotherapy, patients with all-wild-type genes had markedly improved median progression-free survival (12.0 vs. 4.0 months, P < 0.0001) and overall survival (37.0 VS. 24.0 months, P < 0.0001) compared with those with gene mutation; In the cohort of at-least-one gene mutation, patients receiving chemotherapy alone had comparable median PFS (4.0 VS. 4.0 months, P = 0.9498). Moreover, mutated are more common in patients with right-sided colon cancer.
Conclusions
Ten new predictive mutations help to refine the selection of RAS and BRAF wild-type metastatic colorectal cancer patients candidates for anti-EGFRs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
427P - Sahai: A restorative support to address unmet needs of women with cancer – impact on quality of life
Presenter: Poonam Maurya
Session: Poster display session
Resources:
Abstract
428P - A pilot study on comparative efficacy of tramadol or eutectic mixture of local anaesthetics (prilocaine plus lignocaine) in preventing bone marrow aspiration associated pain
Presenter: Bipinesh Sansar
Session: Poster display session
Resources:
Abstract
429P - Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events
Presenter: Sung Yong Oh
Session: Poster display session
Resources:
Abstract
430P - Emetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis
Presenter: Koichi Matsuo
Session: Poster display session
Resources:
Abstract
431P - An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yangrong Tang) for the management of cancer-related fatigue
Presenter: Ning Yi Yap
Session: Poster display session
Resources:
Abstract
432P - Chemotherapy induced extravasation: Incidence and possible predictors
Presenter: Shalaka Somayaji
Session: Poster display session
Resources:
Abstract
433P - Prospective outcomes of adolescent and young adult (AYA) patients received treatment from a tertiary cancer hospital in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: Poster display session
Resources:
Abstract
434P - Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases
Presenter: Sawako Kaku
Session: Poster display session
Resources:
Abstract
435P - Telephonic communication in palliative care for better management of terminal cancer patients in rural India: An NGO based approach
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
436P - Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists
Presenter: Frederic Ivan Ting
Session: Poster display session
Resources:
Abstract